[
  {
    "ts": null,
    "headline": "Finalists Named for the 2026 National ORBIE® Awards",
    "summary": "National ORBIE Awards Honor CIOs and CISOs Advancing Business Growth and Cyber ResilienceSAN JOSE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- For over 25 years, the ORBIE Awards have recognized technology executives for outstanding leadership and business value created by technology innovation and enterprise security. Annually, ORBIE winners from over 50 Inspire Leadership Network chapters across North America are eligible for the National ORBIE Awards. The 2026 National ORBIE Awards finalists ar",
    "url": "https://finnhub.io/api/news?id=700c9f258f27982fd490e9f9da499c76066632a49e5d061dfeb0f5425b6121b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771362840,
      "headline": "Finalists Named for the 2026 National ORBIE® Awards",
      "id": 139126492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "National ORBIE Awards Honor CIOs and CISOs Advancing Business Growth and Cyber ResilienceSAN JOSE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- For over 25 years, the ORBIE Awards have recognized technology executives for outstanding leadership and business value created by technology innovation and enterprise security. Annually, ORBIE winners from over 50 Inspire Leadership Network chapters across North America are eligible for the National ORBIE Awards. The 2026 National ORBIE Awards finalists ar",
      "url": "https://finnhub.io/api/news?id=700c9f258f27982fd490e9f9da499c76066632a49e5d061dfeb0f5425b6121b4"
    }
  },
  {
    "ts": null,
    "headline": "HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\" or the \"Company\") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities.",
    "url": "https://finnhub.io/api/news?id=40ecbc445195f7dca87b75630531cb72b3ae94643d55dfac4072d3d472c96d94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771362060,
      "headline": "HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE",
      "id": 139126581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\" or the \"Company\") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities.",
      "url": "https://finnhub.io/api/news?id=40ecbc445195f7dca87b75630531cb72b3ae94643d55dfac4072d3d472c96d94"
    }
  },
  {
    "ts": null,
    "headline": "Did New KEYTRUDA Approvals Just Shift Merck’s (MRK) Post-Patent Oncology Investment Narrative?",
    "summary": "In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, in PD-L1+ platinum-resistant ovarian, fallopian tube and primary peritoneal cancer, and Health Canada approval of a subcutaneous KEYTRUDA formulation. These additions broaden KEYTRUDA’s clinical reach across tumor types and administration routes, potentially strengthening Merck’s oncology franchise at a...",
    "url": "https://finnhub.io/api/news?id=985d644736c89d2f81f68cd8f0cf281a9d3115f6056497af932f06b06071e43f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771355688,
      "headline": "Did New KEYTRUDA Approvals Just Shift Merck’s (MRK) Post-Patent Oncology Investment Narrative?",
      "id": 139125889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, in PD-L1+ platinum-resistant ovarian, fallopian tube and primary peritoneal cancer, and Health Canada approval of a subcutaneous KEYTRUDA formulation. These additions broaden KEYTRUDA’s clinical reach across tumor types and administration routes, potentially strengthening Merck’s oncology franchise at a...",
      "url": "https://finnhub.io/api/news?id=985d644736c89d2f81f68cd8f0cf281a9d3115f6056497af932f06b06071e43f"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of pembrolizumab, Merck's anti–PD-1 therapy.",
    "url": "https://finnhub.io/api/news?id=e20a155404d92b94008aa53a6e53d16709f1aeb70bc5aee986c551e98a1dd945",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771344000,
      "headline": "Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications",
      "id": 139125078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of pembrolizumab, Merck's anti–PD-1 therapy.",
      "url": "https://finnhub.io/api/news?id=e20a155404d92b94008aa53a6e53d16709f1aeb70bc5aee986c551e98a1dd945"
    }
  },
  {
    "ts": null,
    "headline": "Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?",
    "summary": "BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.",
    "url": "https://finnhub.io/api/news?id=c0c5402bb35ebe74db18d1c27dbe8af06ca7854abe23e2dd188f480f5e69a830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771340400,
      "headline": "Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?",
      "id": 139125079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.",
      "url": "https://finnhub.io/api/news?id=c0c5402bb35ebe74db18d1c27dbe8af06ca7854abe23e2dd188f480f5e69a830"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?",
    "summary": "RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.",
    "url": "https://finnhub.io/api/news?id=287e3a0390db1b1474aae06c4e1d7f5938d464d763afd748eb2677f5c6cc5b35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771339680,
      "headline": "Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?",
      "id": 139125080,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.",
      "url": "https://finnhub.io/api/news?id=287e3a0390db1b1474aae06c4e1d7f5938d464d763afd748eb2677f5c6cc5b35"
    }
  },
  {
    "ts": null,
    "headline": "Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
    "summary": "While the S&P 500 (NYSEARCA:SPY) sits flat year-to-date, the Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) has surged nearly 7%. This shift reflects growing concerns about expensive technology valuations and concentration risk, with the Magnificent Seven trading above 30x earnings on average while comprising over 30% of the S&P 500. COWZ addresses a specific portfolio ... Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
    "url": "https://finnhub.io/api/news?id=d5bd9ac1b35f498290776c12d5b03c7cbd67de07e162744769e89bacda422f85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771337008,
      "headline": "Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
      "id": 139123938,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "While the S&P 500 (NYSEARCA:SPY) sits flat year-to-date, the Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) has surged nearly 7%. This shift reflects growing concerns about expensive technology valuations and concentration risk, with the Magnificent Seven trading above 30x earnings on average while comprising over 30% of the S&P 500. COWZ addresses a specific portfolio ... Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
      "url": "https://finnhub.io/api/news?id=d5bd9ac1b35f498290776c12d5b03c7cbd67de07e162744769e89bacda422f85"
    }
  },
  {
    "ts": null,
    "headline": "10 Health Care Stocks With Whale Alerts In Today's Session",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=bc69404b67565b1e405444a3527ed916cb98692284a20d4aec92df712a69cb1b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335327,
      "headline": "10 Health Care Stocks With Whale Alerts In Today's Session",
      "id": 139133638,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
      "related": "MRK",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=bc69404b67565b1e405444a3527ed916cb98692284a20d4aec92df712a69cb1b"
    }
  },
  {
    "ts": null,
    "headline": "Merck's KEYTRUDA SC Receives Health Canada Approval",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of",
    "url": "https://finnhub.io/api/news?id=8e3da3c8dd4e01e2ea0c8f1fcaef8ffa55f970e4d625cd733c50801272c441e8",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771329826,
      "headline": "Merck's KEYTRUDA SC Receives Health Canada Approval",
      "id": 139133639,
      "image": "",
      "related": "MRK",
      "source": "Benzinga",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of",
      "url": "https://finnhub.io/api/news?id=8e3da3c8dd4e01e2ea0c8f1fcaef8ffa55f970e4d625cd733c50801272c441e8"
    }
  }
]